Pentoxifylline Drug Market , By Product Type (Extended Release Pentoxifylline, Immediate Release Pentoxifylline, Controlled Release Pentoxifylline, and Injectable Pentoxifylline (IV/IM)), By Dosage Strength (100 mg, 300 mg, and 400 mg),By Route of Administration (Oral and Parenteral), By Application (Peripheral Arterial Disease (PAD)/Intermittent Claudication, Chronic Venous Insufficiency, Diabetic Neuropathy, Cerebrovascular Disorders, Raynaud’s Phenomenon, and Sickle Cell Disease Adjunct Use),By Patient Group (Adults (18–64 years), Geriatric Population (65+ years), and Special Cases (renal/hepatic impairment dose-adjusted cohorts), By Drug Type (Branded and Generic), By Prescription Status ( Prescription-Based and Over-the-Counter (OTC)), By Treatment Type (Monotherapy and Combination Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals, Specialty Clinics, Ambulatory Care Centers, and Home-Care/Self-Administration Users), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East and Africa)